Advanced pediatric diffuse pontine glioma murine models pave the way towards precision medicine

Zirong Chen, Peng Peng, Xiaolin Zhang, Barbara Mania-Farnell, Guifa Xi*, Feng Wan

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Diffuse intrinsic pontine gliomas (DIPGs) account for ~15% of pediatric brain tumors, which invariably present with poor survival regardless of treatment mode. Several seminal studies have revealed that 80% of DIPGs harbor H3K27M mutation coded by HIST1H3B, HIST1H3C and H3F3A genes. The H3K27M mutation has broad effects on gene expression and is considered a tumor driver. Determination of the effects of H3K27M on posttranslational histone modifications and gene regulations in DIPG is critical for identifying effective therapeutic targets. Advanced animal models play critical roles in translating these cutting-edge findings into clinical trial development. Here, we review current molecular research progress associated with DIPG. We also summarize DIPG animal models, highlighting novel genomic engineered mouse models (GEMMs) and innovative humanized DIPG mouse models. These models will pave the way towards personalized precision medicine for the treatment of DIPGs.

Original languageEnglish (US)
Article number1114
Pages (from-to)1-17
Number of pages17
JournalCancers
Volume13
Issue number5
DOIs
StatePublished - Mar 1 2021

Keywords

  • Diffuse intrinsic pontine glioma
  • Genetically engineered mouse model
  • Humanized mouse model
  • Molecular biology
  • Patient derived xenografts

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Advanced pediatric diffuse pontine glioma murine models pave the way towards precision medicine'. Together they form a unique fingerprint.

Cite this